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The long and winding road leading to the identiﬁcation
of the hepatitis C virusq
Michael Houghton*
Epiphany Biosciences Inc., One California Street, Suite 2800 San Francisco, CA 94111, USAThis review describes work conducted largely in my laboratory at the Chiron Corporation between 1982 and 1989 that
led to the identiﬁcation of the hepatitis C virus (HCV). Key colleagues included Dr. Qui-Lim Choo in my laboratory and
Dr. George Kuo also of Chiron as well as my collaborator Dr. Daniel Bradley at the CDC who provided many biological
samples from the NANBH chimpanzee model. Numerous molecular approaches were explored including the screening of
tens of millions of bacterial cDNA clones derived from these materials. While this early genomics approach resulted in the
identiﬁcation of many host gene activities associated with NANBH, no genes of proven infectious etiology could be iden-
tiﬁed. A separate avenue of our research led to the molecular characterization of the complete hepatitis delta viral genome
but unfortunately, this could not be used as a molecular handle for HCV. Largely following input from Dr. Kuo, I initiated
a blind cDNA immunoscreening approach involving the large-scale screening of bacterial proteomic cDNA libraries
derived from NANBH-infectious chimpanzee materials (prior to the development of PCR technology) using sera from
NANBH patients as a presumptive source of viral antibodies. Eventually, this novel approach to identifying agents of
infectious etiology led to the isolation of a single small cDNA clone that was proven to be derived from the HCV genome
using various molecular and serological criteria. This discovery has facilitated the development of eﬀective diagnostics,
blood screening tests and the elucidation of promising drug and vaccine targets to control this global pathogen.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Theﬁeld of viral hepatitis was initiated in the 1950s and
60s with the distinction of so-called “infectious” and
“serum” hepatitis [1], later proven to be due to infection
by the hepatitis A virus (HAV) by Dr. Stephen Feinstone
and colleagues at the NIH [2] and by the hepatitis B virus0168-8278/$36.00  2009 European Association for the Study of the Liver.
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tary DNA; TFA, tubule-forming agent.(HBV) by Dr. Baruch Blumberg and colleagues [3],
respectively. With the advent of serological tests to detect
infection by HAV and HBV in the mid-1970s, it was sur-
prising to ﬁnd that most cases of parenterally-transmitted
hepatitis were not in fact due to either virus [4] hence her-
alding the term, Non-A, Non-B hepatitis (NANBH). Dr.
Harvey Alter and other groups then pioneered the use of
the chimpanzee as a reliable model for serial passage of
NANBH infection from human materials [5,6]. The use
of this model provided data indicating the existence of
multiple NANBH agents, one of which was shown to
cause characteristic membranous tubules within the cyto-
plasm of infected chimpanzee hepatocytes (the so-called
tubule-forming agent (TFA; Ref. [7])). Dr. Bradley’s
and Dr. Purcell’s laboratories then went on to show that
the TFA could be inactivated by organic solvents
consistent with it being a lipid-enveloped agent [8,9] andPublished by Elsevier B.V. All rights reserved.
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through a 80 nM pore-sized ﬁlter, Dr. Bradley suggested
in themid-1980s that this could be a small enveloped virus
related to either the ﬂaviviridae, togaviridae or to the hep-
atitis delta agent or alternatively, that it could be a novel
type of enveloped virus [10]. This hypothesis was later fur-
ther reﬁned by Dr. Purcell’s laboratory that showed that
the TFA could pass through a 50 nM ﬁlter [11].
Concurrently, the work of Drs. Harvey Alter, Dien-
stag, Hoofnagle, Seeﬀ and others demonstrated the
insidious development of NANBH disease in humans
with up to 20% of infected patients slowly progressing
to liver cirrhosis typically over the course of many years
[12,13]. Dr. Harvey Alter [14] and separately, the large
TTVS consortium [15], also showed that the incidence
of chronic NANBH was up to 10% following blood
transfusion in the USA. Additional work from Dr. Mir-
iam Alter of the CDC also demonstrated the frequent
acquisition of NANBH within the community, unlinked
with blood transfusion [16].
Despite this progress, it proved impossible to deﬁni-
tively characterize the NANBH agents despite well over
a decade of intensive research by many laboratories
throughout the world [17]. This then was the research
arena that I entered following my emigration from the
UK in 1982, where I had characterized the human inter-
feron-beta gene [18,19], to set up a laboratory at a
newly-formed biotechnology company called Chiron.2. Molecular approaches: 1982–1988
For many years, my laboratory focused on trying to
identify the NANBH genome by cloning nucleic acids
derived from infected human and chimpanzee materials
and then identifying viral clones by showing their spe-
ciﬁc hybridization to radioactive cDNA probes derived
from infected but not uninfected liver or blood samples.
Numerous chimpanzee samples were obtained from my
collaborator Dr. Daniel Bradley of the CDC and some
human samples were provided by Dr. Tatsuo Miyamura
of the Japanese NIH (who worked with me in 1983). By
improving the sensitivity of this +/ hybridization
method and screening many tens of millions of clones
using a cumulative total of 250 mCi of P32-radiola-
belled cDNA, we were able to identify many host-
derived cDNAs speciﬁc to infected samples but none
could be demonstrated to be derived from an etiologic
agent of NANBH.
Given that various studies had suggested a relation-
ship between the NANBH agents and a variety of
known viruses such as the ﬂaviviruses, togaviruses, hep-
adna viruses, picornaviruses and other agents, we used
hybridization probes derived from these viruses in
repeated attempts to identify a signal derived from a
NANBH genome or speciﬁc mRNA. Our inability todo so was interpreted as either being due to limiting
amounts of the NANBH agents in our samples or that
they were novel viruses lacking substantial sequence
identity with the known viruses. In 1977, the hepatitis
delta antigen had been discovered by Dr. Mario Riz-
zetto and shown to be present in the nuclei of some
HBV carriers [20]. This work led to the detection of an
uncharacterized RNA molecule associated with infec-
tious HDV samples from which a small cDNA sequence
had been identiﬁed [21,22]. Because work from Dr. Pur-
cell’s laboratory had shown that HDV infection of
chimpanzees led to the appearance of cytoplasmic
tubules in hepatocytes similar to those observed follow-
ing infection with the NANBH TFA [23], my laboratory
in collaboration with that of Dr. John Gerin went on to
fully characterize the HDV genome and to show that it
was a circular covalently-closed, single-stranded RNA
molecule that extensively base-paired intramolecularly
to form a highly stable double-stranded rod-like struc-
ture, highly reminiscent of plant-like viroids and viru-
soids ([24]; Fig. 1). Evidence that it really was the true
genome of HDV was derived by my colleagues Drs.
Kang-Sheng Wang, Amy Weiner and Qui-Lim Choo
who showed that it did indeed encode the delta antigen
[24,25]. Unfortunately, using the full HDV genome as a
molecular probe for NANBH, Dr. Weiner was unable to
observe speciﬁc hybridization even under conditions of
low stringency [26].
Next, Dr. Weiner developed highly sensitive silver
staining techniques for visualizing electrophoretically-
separated nucleic acids in order to identify high molecu-
lar weight RNA and DNA viral genomes that may be
present in NANBH-infected chimpanzee materials.
Again, no speciﬁc signals were identiﬁed. Concurrently,
Dr. Weiner and other colleagues spent a great deal of
time trying to propagate the NANBH agents in various
tissue culture systems looking for cytolysis or some other
form of cytopathogenic eﬀect possibly induced by suc-
cessful replication of the virus. In addition, we employed
the electron microscope to attempt the visualization of
any viral progeny. Despite some false leads due to con-
taminating endogenous adenoviruses, no evidence for
successful cell culturing of NANBH could be obtained
(we now know that the in vitro propagation of HCV is
extraordinarily diﬃcult and has only been achieved
recently by Dr. Wakita’s laboratory using one speciﬁc
HCV strain derived from a Japanese patient [27]).
A very exciting report from another laboratory con-
cluded that patients clinically-diagnosed with chronic
NANBH exhibited reverse transcriptase (RT) activity
[28]. This stimulated us and many other laboratories
to investigate this claim closely but after extensive anal-
yses, the general conclusion was that no speciﬁc RT
activity was associated with NANBH sera. Similarly, a
report for the in vitro propagation of NANBH-
associated spumaviruses was shown to be due to
Fig. 1. The circular nature of the HDV genome [24]. Reproduced with permission.
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ciﬁc to NANBH [29].
An elegant report described the isolation of human
monoclonal antibodies derived from NANBH patients
that could bind speciﬁcally to NANBH liver sections
and not to control, uninfected liver tissue. It appeared
that for the ﬁrst time, antibodies speciﬁc to the NANBH
agents themselves might have been isolated by Dr.
Yohko Shimizu and colleagues [30]. This stimulated us
to do a large amount of work to obtain such antibodies
and to better deﬁne their reactivity. One method that we
used was immunoscreening of expression cDNA
libraries. We cloned cDNA derived from poly-A+
mRNA obtained from many diﬀerent liver samples from
Dr. Bradley’s NANBH-infected chimpanzees into the
bacteriophage expression vector lambda gt11 and then
screened the resulting proteomic library with Dr. Shi-
mizu’s antibody. As quite often the case with such
immunoscreening experiments, no speciﬁc binding could
be observed. Subsequently however, Dr. Shimizu was
able to purify the reactive antigen from infectious mate-
rials and using sequencing analyses showed that it was in
fact a host-derived protein and not a NANBH viral anti-
gen [31].3. The blind cDNA immunoscreening approach
The isolation of cDNA clones via immunoscreening
of expression plasmid cDNA libraries using monospe-
ciﬁc antisera was ﬁrst developed in the late 1970s [32]
and then further advanced with the development of
bacteriophage expression vectors such as lambda-gt11
[33]. The latter facilitated the large-scale screening of
cDNA libraries due to the use of high plaque densities.While such approaches can be very eﬀective, it was
known that success depended greatly on the quality of
the antibody used and the immunoreactivity proﬁle of
the encoded protein and that this method was not
always successful even when a well-characterized, mono-
speciﬁc polyclonal antisera or monoclonal antibody was
available. In the case of NANBH, no viral-speciﬁc anti-
body had been demonstrated in patient sera despite
numerous investigations by many laboratories [17].
Aligned with the knowledge that NANBH appeared to
develop chronic, persistent disease at a very high rate,
possibly indicating a poor immune response to the etio-
logic agent(s) (as in the case of chronic HBV infection), I
had considered the use of this approach early on in the
program in 1983 and 1984 but had thought it too risky.
In 1985 however, at which time we were actively work-
ing on the seemingly NANBH-speciﬁc antibodies
obtained by Dr. Shimizu, I discussed the sensitivities of
screening for such antibodieswithDr.Kuowhohada lab-
oratory next to mine at Chiron and who was conducting
research on human factor 8, as well as contributing to
the development of a yeast-derived HBV vaccine at
Chiron. The topic of conversation revolved around
Dr. Shimizu’s immunoﬂuorescence assay methods for
identifying such antibodies using target NANBH antigen
present in thin microscopic sections of NANBH-infected
liver biopsies. Since Dr. Bradley had by this time deter-
mined the approximate NANBH infectivity titer of sev-
eral of his chimpanzee liver samples, it was possible to
calculate the approximate average amount of NANBH-
speciﬁc antigen present per hepatocyte, an amount which
Dr. Kuo considered below the detectable limit for such
methods. It was Dr. Kuo who then highly recommended
immunoscreening bacterial expression cDNA libraries
using NANBH patient sera to overcome this limitation
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yield of NANBH antigen per bacterial cell as compared
with that present in infected hepatocytes should no longer
limit the detection of circulating antibodies speciﬁc for the
etiologic agents ofNANBH (provided of course that such
antibodies existed with appropriate aﬃnity and concen-
tration). After further discussions with Dr. Bradley,
who also independently suggested this method as a possi-
ble approach to isolatingHCVand armednowwith a pos-
sible rationale for the failure of numerous groups to detect
circulating antibodies to the NANBH viruses within
patient sera (deriving from input fromDr.Kuo), I decided
to attempt to apply these methods to the identiﬁcation of
HCV cDNA clones, in parallel with the many other
approaches ongoing in my laboratory.
Firstly, Dr. Kuo compared the sensitivities of various
detection methods for screening lambda gt11 cDNA
clones and concluded that the use of I125-radiolabelled
mouse anti-human Ig as a detector antibody was opti-
mal. Next, I made a lambda gt11 cDNA library from
poly-A+ mRNA puriﬁed from biopsy samples obtained
from four diﬀerent NANBH-infected chimpanzees pro-
vided by Dr. Bradley and Dr. Choo demonstrated that
he could detect a rare host mRNA within this library
using a characterized monospeciﬁc antibody. He then
screened this library with a variety of sera samples from
many diﬀerent NANBH-infected chimpanzees and
humans, including apparent convalescent individuals
who might be expected to exhibit a stronger humoral
immune response to try to identify HCV clones but suc-
ceeded only in isolating yet more NANBH-associated
genes but none that could be proven to be derived from
an actual NANBH viral genome itself.
Around this time, Drs. Wang and Choo in my labo-
ratory were involved in characterizing the HDV genome
with a view to using it as a possible hybridization probe
for HCV, work that included the characterization of the
gene encoding the delta antigen. Dr. Weiner had shown
that an open-reading-frame in the anti-genome strand
actually encoded the delta antigen and then Dr. Wang
proceeded to map the B cell epitopes within this antigen.
To do this, we decided to clone very small cDNA frag-
ments (encoding small peptides) from infectious HDV
plasma into lambda gt11 and then screen with human
sera derived from hepatitis delta patients. This experi-
ment worked tremendously well enabling the compre-
hensive and ﬁne mapping of the delta antigen. By this
time, I had received a large quantity of chimpanzee
plasma from Dr. Bradley that he had shown possessed
a NANBH TFA infectivity titer of at least 106 chimpan-
zee infectious doses per ml [34]. As such, this was equiv-
alent to the best titers obtained earlier by other groups
in the ﬁeld (Ref. [35] for example). Bolstered with the
success of the delta antigen mapping study and a knowl-
edge of the relative infectious titers of the HDV and
NANBH plasmas, I was encouraged to extend the blindcDNA immunoscreening approach to Dr. Bradley’s
NANBH chimpanzee plasma. When Dr. Choo screened
a lambda gt11 cDNA library that I had prepared from
this material, none of the positive clones could be
deemed to be derived from the HCV genome. A second
lambda gt11 library that I generated using random
primers of reverse transcriptase from both RNA and
DNA present in the ultra-centrifuged pellet of this chim-
panzee plasma suﬀered from major technical problems
due to oily, viscous contaminants in the extract. Uncer-
tain whether to discard this problematic library and to
start again, we decided eventually to persevere with it
which was then screened by Dr. Choo. This time, we
decided to use serum from a NANBH patient exhibiting
unusually high serum ALT levels as a putative source of
antibodies to the NANBH agent(s). A high ALT is
indicative of very active liver disease and we thought it
possible that this might be accompanied with higher
antibody titers, although we knew at that time that in
the case of HBV infection for example, anti-HBsAg
antibodies are associated with convalescence rather than
active disease (we now know that chronic HCV patients
generally do have higher anti-HCV antibody titers than
convalescent individuals).
When Dr. Choo screened this library, for which we
had but small hope of success due to the technical prob-
lems encountered in its production, he identiﬁed around
six positive clones. Surprisingly, some of these turned
out to be derived from the MS2 bacteriophage RNA
that I had added to the plasma extract as a carrier for
the minute amounts of endogenous nucleic acids pres-
ent. This was a good illustration of the power of this
approach to identify genes that encoded immunoreac-
tive, pathogen-derived antigens (in this case a “virus”
of bacteria). Other clones were shown to be derived
from host genes encoding proteins apparently eliciting
an autoimmune response. Finally, just one small clone
remained (containing about 150 base-pairs and termed
5-1-1 by Dr. Choo) for which eventually, we were able
to show was truly derived from the genome of HCV
(Fig. 2). Ironically, all subsequent cDNA libraries that
I made from this same chimpanzee plasma failed to
contain HCV sequences illustrating the diﬃculties of
cloning tiny amounts of nucleic acid prior to the wide-
spread availability of PCR techniques.4. Proof that clone 5-1-1 was derived from the HCV
genome
First of all, clone 5-1-1 (and overlapping clones identi-
ﬁed from the same cDNA library by routine cross-hybrid-
ization techniques) was shown to be incapable of
hybridising to genomic DNA extracted from control,
uninfected humans and chimpanzees. Secondly, the
clones did hybridise to poly-A+ RNA found only in
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Fig. 2. Schematic of the successful molecular isolation and identiﬁcation of HCV [36]. Reproduced with permission.
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control animals. Thirdly, this RNAwas found to be large
(10,000 nucleotides in length), single-stranded and to be
positive-stranded (i.e. encoded protein). Next, when
expressed in bacteria or yeast, the RNA encoded an anti-
gen that bound to circulating antibodies found only in
parenterally-transmitted,NANBH-infected chimpanzees
and not in HAV- or HBV-infected animals (animal sam-
ples provided by Dr. Bradley). Importantly, these NAN-
BH-infected animals seroconverted to anti-5-1-1 after
acute NANBH infection (example shown in Fig. 3) and
similar seroconversion was observed in a few human
transfusion recipients tested (provided by Dr. Gary Teg-
tmeier) who then went on to develop post-transfusion
NANBH. Moreover, when we checked for the presence
of anti-5-1-1 in a small collection of chronic NANBH
patients (obtained fromDr.GaryGitnick), we found such
antibodies in the majority whereas control, uninfected
humans were negative. Finally, the sequence of clone 5-
1-1 and overlapping clones displayed distant but signiﬁ-
cant sequence identity with the positive-stranded ﬂavivi-
ruses (such as dengue and yellow fever viruses). Taken
together, this constituted ﬁrm evidence that after nearly
6 years of incessant failure, we had ﬁnally identiﬁed a
major etiological agent of parenteral NANBH which we
now termed the hepatitis C virus [36]. The testing algo-rithm for clone 5-1-1 spanned 6 months approximately
meaning that the “eureka moment” was in fact a very
gradual and extended one.5. Developments since the identiﬁcation of HCV
With the ready availability of large amounts of
recombinant HCV antigen (encoded by 5-1-1 and over-
lapping clones), we were now able to produce the ﬁrst
EIA tests for NANBH-speciﬁc antibody which quickly
showed that HCV was the major cause of parenterally-
transmitted NANBH around the world and that these
tests could detect and screen out the majority of infec-
tious blood donors from the blood supply. A blinded
panel of infectious and control blood samples prepared
by Dr. Harvey Alter had hitherto not been successfully
decoded by any putative NANBH test until Dr. Kuo
assayed this panel with our tests [37,38].
Resuming the collaboration with Dr. Tatuso Miyam-
ura’s group in Japan, it quickly became clear that
Japanese strains of HCV had signiﬁcant sequence diver-
gence from our USA-derived strain [39]. We now know
that there is considerable sequence diversity among the
so-called hepaciviruses with at least six major genotypes
identiﬁed and hundreds of diﬀerent sub-types [40]. The
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DAY
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HBV
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0 15 41 129
HAV
C
Fig. 3. Seroconversion to anti-5-1-1 observed after acute NANBH infection of chimpanzees [36]. Reproduced with permission.
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within the ﬂaviviridae family and are very distant relatives
of the ﬂavivirus genus and the pestivirus genus [41]. The
realization of the diversity of HCV has important clinical
implications since while 80–90% of patients infected with
genotypes 2 and 3 are curable with standard-of-care ther-
apy (comprising a combination of pegylated interferon-
alpha plus ribavirin), only around 40–50% of genotype
1 patients are cured by such treatment [42]. Unfortu-
nately, genotype 1 is the most common genotype around
the world [43] and we still do not know the reason for its
incomplete treatment response. This remains an urgent
research priority for the future.
Identiﬁcation of the complete sequence of the HCV
genome allowed the genetic organization to be eluci-
dated [44,45] and the current knowledge of this is sum-
marized in Fig. 4. It immediately became apparent to
us from sequence comparisons with other RNA viruses
that HCV encodes a conserved serine-like protease
domain, a helicase domain and a RNA polymerase
domain [44]. Later work from our and other laborato-
ries conﬁrmed the existence of these enzyme activities
which have been the foci of intensive drug development
and clinical testing work for the last 1–2 decades [45–50].
It is likely that patients will have the beneﬁt of new
drugs targeting some of these enzymes within the next
few years. A key development to facilitate drug testing
and screening as well as basic research was the isolation
of human hepatoma cell-lines that could replicate part
or all of the HCV genome by the laboratory of Dr. Bart-
enschlager [51] and shortly afterwards, by that of
Dr. Rice [52]. Many years later, Dr. Wakita and col-
leagues became the ﬁrst group to produce infectious
virus in cell culture [27].
Various laboratories have elegantly demonstrated the
existence of an additional protease within NS2 [47,53]
which is required for viral production [54], the forma-
tion of a critical ion channel by p7 [55,56] that is also
needed for the production of virus [54,57], a key role
for NS5a in HCV virion assembly and production [58]
and an interaction between NS4b and the viral RNA
genome [59]. A growing understanding of the role of avariety of host proteins in viral replication has also
emerged [60] some of which are now anti-viral targets
(for example cyclophilin which is involved in replicating
the viral RNA genome [61,62]). The requirement for at
least four diﬀerent host proteins (CD81 [63,64], scaven-
ger receptor B1 [65], Claudin-1 [66] and occludin [67])
for entry of HCV into the hepatocyte has also been elu-
cidated. These and other properties of the virus are
opening up many new therapeutic avenues for the esti-
mated 170 million HCV carriers world-wide. In addi-
tion, a potentially important role for the engagement
of CD81 by HCV has been recognized in extra-hepatic
manifestations of HCV-associated diseases such as
non-Hodgkins B cell lymphoma and essential mixed
cryoglobulinemia [68,69].
Prospects for vaccinating against HCV were discour-
aging initially with reports of re-infection in humans
and chimpanzees [70,71]. However, we and others have
now provided evidence for the existence of natural immu-
nity toHCVwhich although not as robust as in the case of
HAV and HBV, signiﬁes none-the-less that a partially
protective HCV vaccine is feasible [72,73]. Indeed, in the
chimpanzee model we have shown that using adjuvanted
recombinant envelope glycoproteins gpE1 and gpE2, it is
possible to protect the majority (80%) of vaccinated
chimpanzees against the development of chronic infection
following experimental challenge with either homologous
or heterologous 1a strains (note that 1a is the most com-
mon sub-type within the USA [74,75]). Further encour-
agement for this approach has been provided by animal
studies demonstrating that this vaccine can cross-neutral-
ize HIV and lentiviral pseudotypes displaying HCV enve-
lope glycoproteins gpE1 and gpE2 derived from multiple
HCV genotypes [76]. Also, a T cell DNA vaccine that elic-
its Thelper and cytotoxicT cell responses to 1bNS3, 4 and
5proteins appears able to protect vaccinated chimpanzees
against experimental challenge with a heterologous 1a
HCV strain [77]. It remains very important to translate
this work in the future into an aﬀordable and global
HCV vaccine since in the USA alone, there are an
estimated 25,000 new HCV infections every year, a level
which must be orders of magnitude higher in the
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Fig. 4. The organization and function of the HCV genome and encoded proteins [88]. Reproduced with permission.
M. Houghton / Journal of Hepatology 51 (2009) 939–948 945developing world [78]. Given that up to 20% of HCV
infections may eventually lead to liver cirrhosis with asso-
ciated risks of hepatocellular carcinoma and end-stage
liver disease, this remains a most urgent goal [12–15,79].
Finally, one is left with admiration for the evolutionary
process that has produced such a highly-adapted RNA
virus that even in the absence of an ability to integrate into
the host genome, can persist for the lifetime of the host in
the majority of infections. The mechanisms underlying
this persistence represent some of the most intriguing
and challenging questions in the ﬁeld and when com-
pletely understood,will open up yetmore therapeutic ave-
nues. Elegant work showing that HCV inhibits the NK
cell response and the induction of type 1 interferon dem-
onstrates the virus’s eﬀectiveness at inhibiting the rapid,
innate immune response to HCV infection [80–82]. The
ability of this highly mutable virus to evolve away from
speciﬁc cellular immune responses has been elegantly doc-
umented [83] as has the existence of infectious virus even
in the presence of an excess of antibody-mediated,
immune-complexed virus (possibly via escape mutations
and/ormasking [84]). It also appears likely that direct cell:
cell transfer of virus contributes to immune-evasion and
viral persistence [85,86] and the ability of this hepatotro-
pic virus to present viral antigen in the liver in such a
way so as to promote immune anergy could be another
potential contributor to viral persistence [87].6. Note added in proof
A set of single nucleotide polymorphisms around and
within the interferon-lambda 3 gene has just been highlycorrelated with treatment response (Ge et al., Nature
Aug 2009).
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